RIPC-HNC: Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial

Sponsor
Aarhus University Hospital Skejby (Other)
Overall Status
Completed
CT.gov ID
NCT02548377
Collaborator
(none)
60
1
2
28.9
2.1

Study Details

Study Description

Brief Summary

The purpose of the trial is to investigate, if remote ischemic preconditioning reduces the risk of complications in patients undergoing resection of head and neck cancer and immediate reconstruction with autologous free tissue transfer.

Remote ischemic preconditioning is a treatment, which is carried out by inducing brief episodes of upper arm occlusion using an inflatable tourniquet.

Blood samples will be taken during the operation and postoperatively to evaluate the effects of remote ischemic preconditioning. These blood samples will be analyzed for clotting properties and markers of inflammation.

Furthermore, effects on the blood supply of the transferred tissue flap will be measured by infrared thermography.

Effects on surgical complication rates will be obtained by clinical follow-up and patient chart review.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Remote ischemic preconditioning
  • Procedure: Sham
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
Actual Study Start Date :
Sep 29, 2015
Actual Primary Completion Date :
Nov 28, 2017
Actual Study Completion Date :
Feb 26, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remote ischemic preconditioning

Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.

Procedure: Remote ischemic preconditioning

Sham Comparator: Sham

The tourniquet will be attached to the patient's upper extremity but never inflated.

Procedure: Sham

Outcome Measures

Primary Outcome Measures

  1. Acute effects on primary hemostasis: Reduced collagen-induced platelet aggregation in whole blood measured by the Multiplate Analyzer. [Blood samples will be analyzed immediately. Data will be assessed and presented within five years.]

Secondary Outcome Measures

  1. Acute effects on secondary hemostasis: Plasma samples will be analyzed by standard coagulation assays. [Plasma samples will be analyzed immediately. Data will be assessed and presented within five years.]

  2. Acute effects on fibrinolysis: Plasma samples will be analyzed for markers of fibrinolysis. [Data will be analyzed, assessed, and presented within five years.]

  3. Acute effects on global hemostasis: Plasma samples will be analyzed with the thrombin generation assay. [Data will be analyzed, assessed, and presented within five years.]

  4. Acute effects on systemic inflammation: Plasma samples will be analyzed for complement, acute-phase proteins, cytokines, and leukocytes. [Data will be analyzed, assessed, and presented within five years.]

  5. Effects on complication rates: Flap complications, systemic complications, morbidity and mortality. [Follow-up is 30 days from the operation. Data will be obtained from visits to the outpatient clinic and by patient chart review. Data will be analyzed, assessed, and presented within five years.]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Histologically verified or clinically suspected malignant tumor in the oral cavity, maxillae, mandible, pharynx, larynx, and/or esophagus.

  • Will undergo tumor resection and immediate free flap reconstruction at Aarhus University Hospital, Denmark.

  • The reconstruction is planned with a single free flap.

Exclusion Criteria:
  • Arterial and/or venous thromboembolism within the last three months.

  • The reconstruction is planned with more than one free flap.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre for Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital Aarhus N Denmark 8200

Sponsors and Collaborators

  • Aarhus University Hospital Skejby

Investigators

  • Study Chair: Anne-Mette Hvas, M.D., Ph.D., Aarhus University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Andreas Engel Krag, M.D., Aarhus University Hospital Skejby
ClinicalTrials.gov Identifier:
NCT02548377
Other Study ID Numbers:
  • RIPC-HNC
First Posted:
Sep 14, 2015
Last Update Posted:
Mar 5, 2018
Last Verified:
Mar 1, 2018
Keywords provided by Andreas Engel Krag, M.D., Aarhus University Hospital Skejby
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 5, 2018